9 pending office actions • 3 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Regenxbio Inc. | 7 |
| Neurimmune AG | 1 |
| Regenxbio, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 19234245 | TREATMENT OF DYSTROPHINOPATHIES WITH MICRODYSTROPHIN GENE THERAPY CONSTRUCTS | Regenxbio Inc. | LEVIN, JOEL D | 1633 | Final Rejection | Jun 10, 2025 |
| 18559078 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY AND COMBINATIONS THEREOF | Regenxbio Inc. | BABIC, CHRISTOPHER M | 1633 | Non-Final OA | Nov 06, 2023 |
| 18259734 | TAU-SPECIFIC ANTIBODY GENE THERAPY COMPOSITIONS, METHODS AND USES THEREOF | Neurimmune AG | SINGH, ANOOP KUMAR | 1632 | Non-Final OA | Jun 28, 2023 |
| 18034330 | VECTORIZED ANTI-CGRP AND ANTI-CGRPR ANTIBODIES AND ADMINISTRATION THEREOF | Regenxbio Inc. | SPENCER, ANDREA LYNNE MORRIS | 1631 | Non-Final OA | Apr 27, 2023 |
| 18034334 | VECTORIZED FACTOR XII ANTIBODIES AND ADMINISTRATION THEREOF | Regenxbio Inc. | SHIBUYA, MARK LANCE | 1631 | Non-Final OA | Apr 27, 2023 |
| 18034039 | VECTORIZED ANTI-TNF-ALPHA ANTIBODIES FOR OCULAR INDICATIONS | Regenxbio, Inc. | ALLEN, SARAH ELIZABETH | 1637 | Non-Final OA | Apr 26, 2023 |
| 18034042 | VECTORIZED TNF-ALPHA ANTAGONISTS FOR OCULAR INDICATIONS | Regenxbio Inc. | HUMPHRIES, NICHOLAS ADAM | 1631 | Non-Final OA | Apr 26, 2023 |
| 18030706 | ADENO-ASSOCIATED VIRUSES FOR OCULAR DELIVERY OF GENE THERAPY | Regenxbio Inc. | THUESON, HANNA MARIE | 1638 | Non-Final OA | Apr 06, 2023 |
| 17628517 | ENGINEERED NUCLEIC ACID REGULATORY ELEMENT AND METHODS OF USES THEREOF | Regenxbio Inc. | MATALKAH, FATIMAH KHALAF | 1638 | Final Rejection | Jan 19, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial